Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells 2,399 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini sold 2,399 shares of the company’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $40.83, for a total transaction of $97,951.17. Following the completion of the transaction, the general counsel now owns 47,088 shares of the company’s stock, valued at $1,922,603.04. The sale was disclosed in a filing with the SEC, which is available at this link.

Jeff Cislini also recently made the following trade(s):

• On Wednesday, June 26th, Jeff Cislini sold 2,000 shares of Revolution Medicines stock. The stock was sold at an average price of $38.47, for a total transaction of $76,940.00.

Revolution Medicines Trading Up 2.1 %

Shares of RVMD stock opened at $43.35 on Friday. The company has a 50 day moving average price of $38.91 and a 200-day moving average price of $33.73. Revolution Medicines, Inc. has a 52 week low of $15.44 and a 52 week high of $44.80.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. During the same quarter in the prior year, the business earned ($0.72) earnings per share. Revolution Medicines’s revenue was down 100.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.12 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on RVMD shares. Oppenheimer increased their price target on shares of Revolution Medicines from $43.00 to $45.00 and gave the stock an “outperform” rating in a research note on Friday, April 12th. Jefferies Financial Group started coverage on shares of Revolution Medicines in a research note on Monday. They issued a “buy” rating and a $63.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $44.00 price target on shares of Revolution Medicines in a research note on Monday, May 13th. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price target on shares of Revolution Medicines in a research note on Thursday, May 9th. Finally, Wedbush increased their price objective on shares of Revolution Medicines from $42.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, May 9th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $45.00.

Institutional Trading of Revolution Medicines

Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP grew its stake in shares of Revolution Medicines by 2.7% in the third quarter. Wellington Management Group LLP now owns 10,572,475 shares of the company’s stock worth $292,646,000 after acquiring an additional 282,786 shares during the period. Bellevue Group AG grew its position in Revolution Medicines by 7.8% during the fourth quarter. Bellevue Group AG now owns 5,091,000 shares of the company’s stock valued at $146,010,000 after buying an additional 369,500 shares during the period. Vanguard Group Inc. grew its position in Revolution Medicines by 3.2% during the third quarter. Vanguard Group Inc. now owns 9,643,591 shares of the company’s stock valued at $266,935,000 after buying an additional 303,088 shares during the period. Walleye Capital LLC bought a new stake in Revolution Medicines during the third quarter valued at approximately $2,644,000. Finally, Mass General Brigham Inc bought a new stake in Revolution Medicines during the first quarter valued at approximately $10,900,000. 94.34% of the stock is currently owned by institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.